New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
11:14 EDTVRX, AKRXAkorn sells ECR Pharmaceuticals unit to Valeant for $41M
Akorn (AKRX) announced that it has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals (VRX) for $41M in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal. In light of this divestiture, Akorn will update its annual 2014 guidance during its Q2 earnings call in early August.
News For AKRX;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
10:00 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTAKRXRBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
08:19 EDTAKRXAkorn management to meet with Deutsche Bank
Subscribe for More Information
06:24 EDTAKRXAkorn initiated with an Overweight, $61 target at JPMorgan
Subscribe for More Information
April 9, 2015
11:39 EDTVRXPershing Square, Valeant, Allergan drop lawsuit over buyout
Subscribe for More Information
April 8, 2015
12:17 EDTAKRX, VRXOn The Fly: Midday Wrap
Subscribe for More Information
11:35 EDTAKRXGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTAKRXGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
April 7, 2015
14:23 EDTAKRXAkorn initiated with a Buy at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use